Evernorth Embarc Benefit Protection®

Uncovering behind-the-scenes challenges in bringing gene therapies to market

Patients getting access to expensive gene therapies is just one of the many challenges to bringing these sometimes life-saving drugs to market.

Mary Dorholt, PharmD, June 07, 22

Gene therapies 101

We answer our clients’ burning questions about gene therapies, including how they work, whether or not they’re safe, and if we’ll see more in the future.

Mary Dorholt, PharmD, February 12, 20

Understanding Gene Modification and Cellular Therapies

Gene modification and cellular therapies are unique, potentially curative treatments that leverage gene-altering technology

Mary Dorholt, PharmD, June 02, 21

We’re on the verge of a breakthrough for gene therapies

The first gene therapies have come to market. Hundreds more are in the drug pipeline.

Mary Dorholt, PharmD, July 08, 21

What to look for in the upcoming gene therapy pipeline

As the gene therapy landscape continues to evolve, plan sponsors should familiarize themselves with the tools and strategies necessary to navigate the future of these game-changing treatments.

Mary Dorholt, PharmD, April 20, 23

How to have a data-driven discussion on gene and cellular therapies

As the number of approved gene and cellular therapies grows, you can start preparing your organization now by taking the right next steps.

Mary Dorholt, PharmD, October 28, 21

Gene Therapy: Proper Care for This Life-Saving Innovation

Evernorth is focused on providing appropriate clinical and financial management for gene therapies coming to market.

July 27, 20

Ensuring Coverage is Key For Life Altering Gene Therapies

Access, cost can be insurmountable hurdles unless the patient’s plan has the proper strategies in place

Jackie Huntebrinker, August 19, 21

Understanding Hemophilia

Breaking down the challenges, therapies and costs associated with hemophilia.

Mary Dorholt, PharmD, March 15, 23